miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM)

View original at finance.yahoo.com
Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM) Looking back on mixed or offshore upstream e&p stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including SM Energy (NYSE:SM) and its peers…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SM Energy Q1 2026 revenues of $1.48 billion exceeded analysts' expectations by 5.8%, with beats also on EPS and EBITDA estimates.

    60% confidence

  • On average, shares of the 21 tracked mixed or offshore upstream E&P companies are down 6.8% since the latest earnings results.

    60% confidence

  • Smaller or niche E&P companies face headwinds including higher operational and geological risks, limited scale, constrained capital market access, and disproportionate regulatory and ESG risks.

    60% confidence

  • As a group, the 21 mixed or offshore upstream E&P stocks reported Q1 revenues that missed analysts' consensus estimates by 5%.

    60% confidence

  • Seadrill Q1 2026 revenues of $358 million outperformed analysts' expectations by 7.2%, with beats also on EPS and EBITDA estimates.

    60% confidence

  • SM is off to an outstanding start in 2026.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Mixed or Offshore Upstream E&P Stocks Q1 Recap: Benchmarking SM Energy (NYSE:SM) — Source | Via News | es.VIA.NEWS